Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

105.43
+0.75000.72%
Volume:131.98K
Turnover:13.81M
Market Cap:4.79B
PE:51.43
High:105.48
Open:104.35
Low:103.65
Close:104.68
52wk High:110.45
52wk Low:48.17
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.55
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.72
PE(LYR):51.43

Loading ...

Haemonetics Is Maintained at Outperform by Barrington Research

Dow Jones
·
May 13

Press Release: Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 13

Barrington Cuts Price Target on Haemonetics to $89 From $94, Keeps Outperform Rating

MT Newswires Live
·
May 12

Haemonetics Earnings Call Highlights Growth Amid Headwinds

TIPRANKS
·
May 09

Haemonetics Is Maintained at Neutral by JP Morgan

Dow Jones
·
May 09

Haemonetics price target lowered to $67 from $72 at Baird

TIPRANKS
·
May 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Haemonetics (HAE), Scholar Rock Holding (SRRK) and Ocugen (OCGN)

TIPRANKS
·
May 08

Stock Track | Haemonetics Soars 8.22% in Pre-market on Strong Q4 Earnings Beat and Upbeat Fiscal 2027 Guidance

Stock Track
·
May 07

Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Net Revenue $346.4M, vs. FactSet Est of $336.8M

MT Newswires Live
·
May 07

Haemonetics Corp Q4 REV View $336.9 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
May 07

Haemonetics Corp - Fiscal 2027 Guidance Reported Revenue 4% - 7% - SEC Filing

THOMSON REUTERS
·
May 07

Haemonetics Corp -Fiscal 2027 Guidance Adjusted Earnings per Diluted Share Is Comparable to Revenue Growth- SEC Filing

THOMSON REUTERS
·
May 07

Haemonetics Q4 Adj. EPS $1.29 Beats $1.27 Estimate, Sales $346.351M Beat $336.862M Estimate

Benzinga Earnings
·
May 07

Haemonetics Q4 Revenue USD 346.4 Million VS. Ibes Estimate USD 336.9 Million

THOMSON REUTERS
·
May 07

Haemonetics Outlook FY Organic Growth 3-6%

THOMSON REUTERS
·
May 07

Haemonetics Q4 EPS USD -0.44

THOMSON REUTERS
·
May 07

Haemonetics Q4 FY26 swings to loss of ($0.44) per share; revenue rises 4.8% to $346.4 million

Reuters
·
May 07

Press Release: Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Dow Jones
·
May 07

Haemonetics CEO Simon joins Bank of America Healthcare Conference fireside chat

Reuters
·
May 05

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

GlobeNewswire
·
May 04